MGO One Seven LLC Sells 2,647 Shares of Sanofi $SNY

MGO One Seven LLC lowered its position in shares of Sanofi (NASDAQ:SNY) by 9.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,259 shares of the company’s stock after selling 2,647 shares during the period. MGO One Seven LLC’s holdings in Sanofi were worth $1,220,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. Brighton Jones LLC grew its position in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares during the last quarter. Farther Finance Advisors LLC grew its position in Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock worth $338,000 after acquiring an additional 2,476 shares during the last quarter. GAMMA Investing LLC grew its position in Sanofi by 58.7% during the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after acquiring an additional 2,241 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Sanofi by 3.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 339,437 shares of the company’s stock worth $18,825,000 after buying an additional 11,806 shares during the period. Finally, Sowell Financial Services LLC acquired a new position in Sanofi during the 1st quarter worth about $328,000. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of several recent research reports. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Down 0.5%

Shares of NASDAQ:SNY opened at $48.96 on Thursday. The company has a market capitalization of $120.22 billion, a price-to-earnings ratio of 11.77, a P/E/G ratio of 1.20 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The business’s 50-day moving average is $48.37 and its 200-day moving average is $49.69. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 earnings per share. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.